Falkenhain-Lopez, D, Muniesa, C, Estrach, MT, Morillo-Andujar, M, Penate, Y, Acebo, E, Pujol, RM, Garcia-Muret, MP, Machan, S, Medina, S, Botella-Estrada, R, de Misa, RF, Blanes, M, Florez, A, Perez-Paredes, G, Izu, R, Yanguas, I, Silva-Diaz, E, Perez-Ferriols, A, Prieto-Torres, L, Zayas, A, Parera-Amer, ME, Perez, A, Aspe, L, Roman, C, Sanchez-Caminero, MP, Bassas-Vila, J, Dominguez-Aunon, JD, Calzado, L, Navedo, M, Ortiz-Prieto, A, Servitje, O, Polo-Rodriguez, I, Torres, I, Hernandez-Hernandez, MN, Mitxelena-Eceiza, J, Garcia-Vazquez, A, Garcia-Doval, I, Ortiz-Romero, PL. Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years. Actas Dermo-Sifiliograficas. 2023; 114(4)DOI:10.1016/j.ad.2022.11.013. PMID:36848951. IF:(Q/D).

Escale-Besa, A, Yelamos, O, Vidal-Alaball, J, Fuster-Casanovas, A, Catalina, QM, Borve, A, Aguilar, RAE, Fusta-Novell, X, Cubiro, X, Rafat, ME, Lopez-Sanchez, C, Marin-Gomez, FX. Exploring the potential of artificial intelligence in improving skin lesion diagnosis in primary care. Scientific Reports. 2023; 13(1)DOI:10.1038/s41598-023-31340-1. PMID:36922556. IF:3.800(Q1/2D).

Egeberg A., Merola J.F., Schaekel, K, Puig L., Mahar P.D., Wang I.Y., Pavo I., Schuster C., Griffiths, CEM. Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes (vol 9, 1092688, 2023). Frontiers in Medicine. 2023; 10DOI:10.3389/fmed.2023.1171132. PMID:36974067. IF:3.100(Q1/2D).

Kokolakis, G, Warren, RB, Strober, B, Blauvelt, A, Puig, L, Morita, A, Gooderham, M, Korber, A, Vanvoorden, V, Wang, M, de Cuyper, D, Madden, C, Gomez, NN, Lebwohl, M. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. BRITISH JOURNAL OF DERMATOLOGY. 2023; 188(3)DOI:10.1093/bjd/ljac089. PMID:36751950. IF:11.000(Q1/1D).